Výsledky vyhledávání

Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis

Autor: Mark Ling, W. Philip Werschler, Dow Stough, George J. Schmieder, Janelle Katsamas, Lawrence L. Anderson, Eduardo Tschen

Publikováno v: Journal of the American Academy of Dermatology. 60:934-943

There is a need for improved medical approaches to the treatment of actinic keratosis. Ingenol mebutate, a diterpene ester extracted and purified from the plant Euphorbia peplus, is being evaluated as a topical therapy for actinic keratosis.Assess th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::433513140fdb63ecabbb382b84749015
https://doi.org/10.1016/j.jaad.2009.01.008

Zobrazit plný text záznamu

Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Lidocaine/Tetracaine Patch for Induction of Local Anesthesia prior to Minor Dermatologic Procedures in Geriatric Patients

Autor: Robert J. Pariser, Neil S. Sadick, Mark Ling, Amy K. Schecter, Daniel Stewart, David M. Pariser

Publikováno v: Dermatologic Surgery. 31:287-291

Background Topical anesthetics offer a noninvasive method of anesthesia. Objective To evaluate the efficacy and safety of the lidocaine/tetracaine patch, a 1:1 (wt:wt) eutectic mixture of lidocaine and tetracaine, for local anesthesia before minor de

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b44c76e37b6eb28bd068bfd8cb6aaa27
https://doi.org/10.1097/00042728-200503000-00006

Zobrazit plný text záznamu

A randomized study of the safety, absorption and efficacy of pimecrolimus cream 1% applied twice or four times daily in patients with atopic dermatitis

Autor: Alice B. Gottlieb, Ken Abrams, Mark Ling, David M. Pariser, Graham Scott, Ivan Caro, Daniel Stewart

Publikováno v: Journal of Dermatological Treatment. 16:142-148

Pimecrolimus cream 1% (Elidel), a non-steroid inhibitor of inflammatory cytokines, is effective in the treatment of atopic dermatitis, without corticosteroid-related side effects such as skin atrophy. It is indicated for twice-daily application. More

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab233b1284b91a679772c2c6508ac8ec
https://doi.org/10.1080/09546630510033159

Zobrazit plný text záznamu

Plný text ve formátu HTML

Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: A double-blind, randomized study

Autor: Alan Menter, Alice B. Gottlieb, Zoe Diana Draelos, Mark Ling, Carin H. Gribetz, Thomas Hultsch, Nardo Zaias, Mark Lebwohl, Anne Parneix-Spake, Diana M. Chen, David M. Pariser

Publikováno v: Journal of the American Academy of Dermatology. 51:731-738

Background Inverse psoriasis can be difficult to treat because of the high sensitivity of intertriginous areas to cutaneous side effects, such as irritation and striae. Pimecrolimus, a well-tolerated, nonatrophogenic, skin-selective inflammatory cyto

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4fb47e7fa466a5b12c539365f5b092eb
https://doi.org/10.1016/j.jaad.2004.06.010

Zobrazit plný text záznamu

Subcutaneously Administered Efalizumab (Anti-CD 11a) Improves Signs and Symptoms of Moderate to Severe Plaque Psoriasis

Autor: Alice B. Gottlieb, Patricia A. Walicke, Nicholas J. Lowe, Ross Bright, Robert J. Bauer, Charles Hudson, Toivo Rist, Anna Magee, Wolfgang Dummer, Mark White, William Shapiro, Bruce E. Miller, Marvin Garovoy, Calvin O. McCall, Mark Ling

Publikováno v: Journal of Cutaneous Medicine and Surgery. 7:198-207

Background: Phase I and Phase II studies in patients with moderate to severe plaque psoriasis demonstrated that intravenous (TV) efalizumab improved clinical signs and symptoms and was well tolerated. Objective: To determine if subcutaneous (SC) deli

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::417528a57cb8459bc2eed0368d2e75b9
https://doi.org/10.1177/120347540300700303

Zobrazit plný text záznamu

Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections

Autor: Alan B. Fleischer, Eileen Jaracz, Mark Ling, Yoichi Satoid, Lawrence F. Eichenfield, M. Joyce Rico, Rochelle M. Maherd

Publikováno v: Journal of the American Academy of Dermatology. 47:562-570

Objective: The purpose of this study was to evaluate the risk of cutaneous infection in patients with atopic dermatitis treated with tacrolimus ointment. Methods: Data for 1554 patients with atopic dermatitis, treated with tacrolimus ointment in 5 cl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e679da700dde618b7bf5edf4bbba82d
https://doi.org/10.1067/mjd.2002.124603

Zobrazit plný text záznamu

Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part I, efficacy

Autor: Mark Ling, Debra L. Breneman, Jon M. Hanifin, Richard G. Langley, Elyse S. Rafal

Publikováno v: Journal of the American Academy of Dermatology. 44:S28-S38

A total of 632 adults with atopic dermatitis applied tacrolimus ointment (0.03% or 0.1%) or vehicle twice daily for up to 12 weeks in two randomized, double-blind studies. This report focuses on the efficacy of tacrolimus ointment in these studies. T

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5047248ca89b52a30b488acd601894d6
https://doi.org/10.1067/mjd.2001.109810

Zobrazit plný text záznamu

EXTEMPORANEOUS COMPOUNDING

Autor: Mark Ling

Publikováno v: Dermatologic Clinics. 16:321-327

Extemporaneous compounding has long been a part of dermatology. It has served to produce niche therapies that otherwise would have been poorly treated with available drugs. Increasingly however, the unpredictable nature of compounded medications, bot

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fd1a9ac7fde9b3e91ad1cae92dd2265c
https://doi.org/10.1016/s0733-8635(05)70014-0

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání